Nesiritide (Scios)
Related Experiment Video
Updated: Sep 25, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Andrew J Burger1, Mary R Burger
1Beth Israel Deaconess Medical Center, Non-invasive Cardiology Laboratory, Baker-3, 1 Deaconess Road, Boston, MA 02215, USA. aburger@caregroup.harvard.edu
Abstract:
Nesiritide is a recombinant B-type (brain) natriuretic peptide developed by Scios for the potential treatment of congestive heart failure (CHF). In August 2001, the product was approved and launched in the US for the intravenous treatment of patients with acute decompensated congestive heart failure (ADCHF) who have dyspnea at rest or at minimal activity [418946], [420072]. By March 2002, Scios' European development partner, GlaxoSmithKline, expected to file a Marketing Authorization Application (MAA) for nesiritide in Europe in 2002 [446957].
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Respiratory Syncytial Virus Disease
Heart Failure Drugs: Inotropic Agents
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure II: Pathophysiology
Cardiopulmonary Resuscitation IV: Pharmacological Management
